Zaya MJ[au] - Search Results

Year	Number of Results
1989	1
1990	1
1991	1
1995	1
2001	1
2003	3
2006	1
2008	2
2009	1
2010	2
2011	1
2014	1
2018	1
2019	1
2022	0

1

Comparison of predicted intrinsic hepatic clearance of 30 pharmaceuticals in canine and feline liver microsomes.

Visser M, Zaya MJ, Locuson CW, Boothe DM, Merritt DA. Visser M, et al. Among authors: zaya mj. Xenobiotica. 2019 Feb;49(2):177-186. doi: 10.1080/00498254.2018.1437933. Epub 2018 Mar 6. Xenobiotica. 2019. PMID: 29405805

2

Epirubicin glucuronidation and UGT2B7 developmental expression.

Zaya MJ, Hines RN, Stevens JC. Zaya MJ, et al. Drug Metab Dispos. 2006 Dec;34(12):2097-101. doi: 10.1124/dmd.106.011387. Epub 2006 Sep 19. Drug Metab Dispos. 2006. PMID: 16985101

3

Development of an in vitro screen for compound bioaccumulation in Haemonchus contortus.

Zhou X, Deng JN, Hummel BD, Woods DJ, Collard WT, Hu SX, Zaya MJ, Knauer CS, Thompson DP, Merritt DA, Lorenz JK, Marchiondo AA. Zhou X, et al. Among authors: zaya mj. J Parasitol. 2014 Dec;100(6):848-55. doi: 10.1645/14-556.1. J Parasitol. 2014. PMID: 25116000

4

Developmental changes in human liver CYP2D6 expression.

Stevens JC, Marsh SA, Zaya MJ, Regina KJ, Divakaran K, Le M, Hines RN. Stevens JC, et al. Among authors: zaya mj. Drug Metab Dispos. 2008 Aug;36(8):1587-93. doi: 10.1124/dmd.108.021873. Epub 2008 May 12. Drug Metab Dispos. 2008. PMID: 18474679

5

A non-acidic sulfaphenazole analog demonstrating high intrinsic clearance and selectivity by canine CYP2C21.

Locuson CW, Alfaro JF, Zaya MJ, Billen D, White JA, Jones JP. Locuson CW, et al. Among authors: zaya mj. Drug Metab Lett. 2011 Dec;5(4):253-8. doi: 10.2174/187231211798472539. Drug Metab Lett. 2011. PMID: 22423626

6

Canine CYP2B11 metabolizes and is inhibited by anesthetic agents often co-administered in dogs.

Baratta MT, Zaya MJ, White JA, Locuson CW. Baratta MT, et al. Among authors: zaya mj. J Vet Pharmacol Ther. 2010 Feb;33(1):50-5. doi: 10.1111/j.1365-2885.2009.01101.x. J Vet Pharmacol Ther. 2010. PMID: 20444025

7

Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs.

Mills BM, Zaya MJ, Walters RR, Feenstra KL, White JA, Gagne J, Locuson CW. Mills BM, et al. Among authors: zaya mj. Drug Metab Dispos. 2010 Mar;38(3):396-404. doi: 10.1124/dmd.109.030429. Epub 2009 Dec 9. Drug Metab Dispos. 2010. PMID: 20007294

8

Developmental expression of the major human hepatic CYP3A enzymes.

Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, Zaya MJ. Stevens JC, et al. Among authors: zaya mj. J Pharmacol Exp Ther. 2003 Nov;307(2):573-82. doi: 10.1124/jpet.103.054841. Epub 2003 Sep 15. J Pharmacol Exp Ther. 2003. PMID: 12975492

9

Expression and characterization of functional dog flavin-containing monooxygenase 1.

Stevens JC, Melton RJ, Zaya MJ, Engel LC. Stevens JC, et al. Among authors: zaya mj. Mol Pharmacol. 2003 Feb;63(2):271-5. doi: 10.1124/mol.63.2.271. Mol Pharmacol. 2003. PMID: 12527797

10

In vitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibition.

Aidasani D, Zaya MJ, Malpas PB, Locuson CW. Aidasani D, et al. Among authors: zaya mj. Drug Metab Dispos. 2008 Aug;36(8):1512-8. doi: 10.1124/dmd.108.021196. Epub 2008 Apr 30. Drug Metab Dispos. 2008. PMID: 18448570

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results